At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
DSP-1349M +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled, Single Ascending Dose Study With Lurasidone Injectable Suspension to Evaluate Safety, Tolerability and Pharmacokinetics in Subjects With Schizophrenia
In Brief
A Phase 1 clinical trial evaluating DSP-1349M and placebo for Schizophrenia. Completed, enrolled 40 participants across 1 site.
Detailed Summary
A study to determine the maximum tolerated dose of an investigational drug in subjects with schizophrenia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedAug 2018
Primary CompletionMar 2019
TodayJul 2026
First PostedAug 13, 2018
Enrollment StartJun 7, 2018
Primary CompletionMar 29, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.9 years ago
Interventions
DSP-1349Mdrug
DSP-1349M injectable
placebodrug
placebo injection